gdc
LeukemiaLymphomaNewsworthy

Celebrating Progress and Sharing Hope: The Leukemia & Lymphoma Society to Host Free Rocky Mountain Blood Cancer Conference for Blood Cancer Patients, Survivors and Caregivers

The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.
Press Releases

DENVER, CO, TUESDAY, MARCH 20, 2018 – The Leukemia & Lymphoma Society® (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.

Local experts from the Colorado Blood Cancer Institute, Kaiser Permanente, Rocky Mountain Cancer Centers and University of Colorado will be updating attendees on the latest in blood cancer research and treatments. Additionally, Caregiver Support will be addressed in the keynote speech by Kimberly Alexander, Principal Consultant at KimCONNECTS.

Conference attendees can look forward to topics like:

  • Car-T Cell Therapies
  • Diagnosis Specific Information
  • Health and Wellness
  • Survivorship and Life After Cancer

“Every year hundreds of patients, caregivers and healthcare providers come together to educate themselves on blood cancer. We are pleased to offer this conference to our community and to see first-hand the impact it has on our residents.” –Rebecca Russell, Executive Director, Rocky Mountain Chapter of The Leukemia & Lymphoma Society

LLS is a catalyst for collaboration within the cancer ecosystem, bringing together industry, government, healthcare providers and academia to develop new and better therapies and accelerate cures. Blood cancer research is the gateway to treatments for many cancers and other serious diseases. LLS is doing more than any health non-profit organization to advance cures and access for blood cancer patients and is having an impact beyond the blood cancers.

The conference enables blood cancer patients and caregivers to network, share, and feel empowered.

For additional information or to register, please visit https://www.eiseverywhere.com/ehome/rmbcc18/641031/ or call (720) 440-8627.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

THE ROCKY MOUNTAIN CHAPTER OF THE LEUKEMIA & LYMPHOMA SOCIETY
720 S. COLORADO BLVD., STE 500-S, DENVER, CO 80246
720-440-8620

Recommended For You
Leukemia
Information Is Power: Targeted Therapies Extend Survival for Patients with Chronic Lymphocytic Leukemia
By Dan Dean
At the June 2019 annual meeting of the American Society of Clinical Oncology (ASCO), 2 experts discussed the implications of new treatments for chronic lymphocytic leukemia (CLL). The blood cancer known as CLL is often diagnosed late, and until recently the initial treatment was chemotherapy alone. However, new non-chemotherapy targeted therapies have been approved by the FDA in the past few months for use as the first (or first-line) treatment for patients with CLL.
FDA Approvals, News & UpdatesNewsworthyWeb Exclusives
FDA and CDC Investigate Outbreak of Vaping-Related Illness
In the past week, the US Food and Drug Administration (FDA) has released 2 public announcements related to the use of vaping products.
FDA Approvals, News & UpdatesLymphomaNewsworthy
Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma
In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
Last modified: March 27, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country